Aknar Calabrich

Durvalumab plus platinum–etoposide versus platinum–etoposide in first-line treatment of extensive-stage small-cell lung cancer (CASPIAN): a randomised, controlled, open-label, phase 3 trial

Luis Paz‐Ares, Mikhail Dvorkin, Yuanbin Chen et al. · The Lancet · 2019 · 2.1K citations

Platinum–etoposide Versus Platinum–etoposide, Medicine, Pharmacology +6

Durvalumab, with or without tremelimumab, plus platinum–etoposide versus platinum–etoposide alone in first-line treatment of extensive-stage small-cell lung cancer (CASPIAN): updated results from a randomised, controlled, open-label, phase 3 trial

Jonathan W. Goldman, Mikhail Dvorkin, Yuanbin Chen et al. · The Lancet Oncology · 2020 · 662 citations · Full text

Platinum–etoposide Versus Platinum–etoposide, Medicine, Pathology +6

Differential properties of CBA/J mononuclear phagocytes recovered from an inflammatory site and probed with two different species of Leishmania

Ivana Nunes Gomes, Aknar Calabrich, Rafael da Silva Tavares et al. · Microbes and Infection · 2003 · 61 citations · Full text

Inflammation, Autoimmune Disease, Differential Properties +12

Oncology practice during COVID-19 pandemic: a fast response is the best response

Cinthya Sternberg, Thamine Lessa Andrade, Ana Paula Gomes Alcântara Villa Nova et al. · Revista da Associação Médica Brasileira · 2020 · 29 citations · Full text

Brazilian guidelines for the management of immune-related adverse events associated with checkpoint inhibitors

Alberto Julius Alves Wainstein, Aknar Calabrich, Andréia Cristina de Melo et al. · 2017 · 24 citations

Checkpoint Inhibitors, Medicine, Brazilian Guidelines +8